rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
|
18523885 |
2009 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our study suggests there might be an association between the TGFβ1 29C>T polymorphism and CVD risk in long-term breast cancer survivors.
|
22100658 |
2012 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data suggest that the TGF-beta1 Leu10Pro polymorphism might play a role in breast cancer risk.
|
17035001 |
2007 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Transforming growth factor β1 (TGFB1) T29C and TGF β receptor type 1 (TGFBR1) 6A/9A polymorphisms have been implicated in the modulation of risk for breast cancer in Caucasian women.
|
21829601 |
2011 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Transforming growth factor β1 (TGFB1) T29C and TGF β receptor type 1 (TGFBR1) 6A/9A polymorphisms have been implicated in the modulation of risk for breast cancer in Caucasian women.
|
21829601 |
2011 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conclude that the TGFB1 L10P polymorphism is not associated with breast cancer risk.
|
14607332 |
2003 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
It can be concluded that TGF-β1 29T/C polymorphism does not play a role in breast cancer susceptibility in overall or ethnicity-specific manner.
|
25374198 |
2014 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
For five SNPs--CASP8 D302H, IGFBP3 -202 c>a, PGR V660L, SOD2 V16A, and TGFB1 L10P--the associations with breast cancer were of borderline statistical significance (P = .016, .060, .047, .056, and .0088 respectively).
|
17018785 |
2006 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our analysis suggested that 29T/C</span> has no association with a trend of breast cancer</span> risk when using both dominant [odds ratio (OR) = 1.01, 95% confidence intervals (CI) 0.96-1.07] and recessive models (OR = 0.98, 95% CI 0.89-1.08) to analyze the data.
|
20845106 |
2010 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the potential influences of TGF-beta1 T29C and TNF-beta A252G gene polymorphisms on breast cancer risk, a case-control study was conducted in Korea.
|
15803361 |
2005 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
A T29C transition polymorphism in the TGFB1 gene has been associated with higher circulating TGF-beta1 levels, and inconsistently with breast cancer risk in three recent studies.
|
15006917 |
2004 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
c.29C>T and c.74G>C polymorphisms in the TGF-β1 gene significantly affect breast cancer risk, which correlates with elevated TGF-β1 level in the patients.
|
24146803 |
2013 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The purposes of this study were to analyse the genotype of TGF-beta1 at T29C and TGF-beta1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer.
|
18827819 |
2008 |
rs1800470
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, no significant associations between the TGFB1 T29C polymorphism and breast cancer risk were found for CC versus TT (OR = 1.00, 95% CI = 0.92-1.09), TC versus TT (OR = 0.98, 95% CI = 0.93-1.05), CC/TC versus TT (OR = 0.99, 95% CI = 0.93-1.05), and CC versus TC/TT (OR = 1.00, 95% CI = 0.93-1.08).
|
20157775 |
2010 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our analysis suggested that 29T/C</span> has no association with a trend of breast cancer</span> risk when using both dominant [odds ratio (OR) = 1.01, 95% confidence intervals (CI) 0.96-1.07] and recessive models (OR = 0.98, 95% CI 0.89-1.08) to analyze the data.
|
20845106 |
2010 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Conclusively, this meta-analysis strongly suggests that TGFB1 L10P polymorphism may play a low penetrance role in breast cancer susceptibility in Caucasian.
|
20349130 |
2010 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Consecutive patients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) and healthy females (n = 880) from New York City were genotyped for the hypomorphic TGFBR1*6A allele and for the TGFB1 T29C variant that results in increased TGF-beta circulating levels.
|
15833881 |
2005 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects.
|
20143152 |
2010 |
rs1800470
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
|
18523885 |
2009 |
rs1800470
|
|
Osteoporosis
|
|
0.050 |
GeneticVariation
|
BEFREE |
Transforming growth factor-beta1 is an important local regulator of bone metabolism, acting downstream of estrogen and cooperatively with vitamin D. The possible association of a C 509-->T polymorphism in the promoter region of the transforming growth factor-beta1 gene, alone or in combination with a T869-->C (Leu10-->Pro) polymorphism, with bone mineral density and genetic susceptibility to osteoporosis was investigated in 625 postmenopausal Japanese women.
|
11357939 |
2001 |
rs1800470
|
|
Osteoporosis
|
|
0.050 |
GeneticVariation
|
BEFREE |
We have shown that a T869-->C polymorphism of the transforming growth factor-beta1 gene, which results in a Leu-->Pro substitution at amino acid 10, is associated with bone mineral density in Japanese adolescents and postmenopausal women, with genetic susceptibility to both osteoporosis and vertebral fracture, and with the outcome of treatment for osteoporosis with active vitamin D. We have also shown that a C-509-->T polymorphism in the promoter region of this gene is associated with both bone mineral density and the prevalence of osteoporosis in postmenopausal women.
|
11740340 |
2001 |
rs1800470
|
|
Osteoporosis
|
|
0.050 |
GeneticVariation
|
BEFREE |
TGF-beta1 is commonly associated with a single base change resulting in a Leu(10)-->Pro (T(869)-->C) polymorphism and is a genetic marker for susceptibility to osteoporosis.
|
12706579 |
2003 |
rs1800470
|
|
Osteoporosis
|
|
0.050 |
GeneticVariation
|
BEFREE |
In this study, we investigated the association between osteoporosis and interleukin 10 (IL-10) -597 C > A and transforming growth factor β1 (TGF-β1) T869C (also named Leu10 > Pro) polymorphisms in Turkish postmenopausal women.
|
23583365 |
2013 |
rs1800470
|
|
Osteoporosis
|
|
0.050 |
GeneticVariation
|
BEFREE |
We have shown that a T(869)-->C polymorphism of the transforming growth factor-beta1 (TGF-beta1) gene, which results in a Leu-->Pro substitution at amino acid 10, is associated with bone mineral density in Japanese adolescents and postmenopausal women, with genetic susceptibility to osteoporosis or spinal osteoarthritis, and with the outcome of treatment for osteoporosis with active vitamin D. I here review our recent studies, which have provided insight into the function of TGF-beta1 as well as into the role of genetic factors in the development of osteoporosis and osteoarthritis.
|
10996011 |
2000 |
rs1800470
|
|
Chronic Obstructive Airway Disease
|
|
0.030 |
GeneticVariation
|
BEFREE |
Of these variants, four were significantly associated with COPD susceptibility in random effects meta-analysis, the GSTM1 null variant (OR 1.45, CI 1.09-1.92), rs1800470 in TGFB1 (0.73, CI 0.64-0.83), rs1800629 in TNF (OR 1.19, CI 1.01-1.40) and rs1799896 in SOD3 (OR 1.97, CI 1.24-3.13).
|
19933216 |
2010 |